HDBRAIN: Taking Brain Monitoring to the Next Level

Sponsor
University of California, Los Angeles (Other)
Overall Status
Recruiting
CT.gov ID
NCT04246320
Collaborator
(none)
60
1
1
41
1.5

Study Details

Study Description

Brief Summary

This one arm clinical study will assess the impact of a goal directed therapy intervention, aiming at optimizing depth of anesthesia and intraoperative blood pressure on the incidence of postoperative cognitive dysfunction and delirium relative to a standardized anesthetic plan. We will enroll 60 patients and will measure the neurocognitive status (MoCA test) of patients before and after surgery (at discharge, within 2 weeks after surgery and 6 months after surgery) to determine the relative impact of anesthetic care on the development of postoperative delirium and cognitive decline. All patients will have a brain scan (fMRI) before and after surgical intervention. Patients will also be asked to participate in an optional blood draw which will take place during their brain imaging visit and post operatively (within 2 days after surgery).

Condition or Disease Intervention/Treatment Phase
  • Other: Goal directed therapy (GDT)
N/A

Detailed Description

This study will test the hypothesis that a goal directed therapy intervention, which optimizes depth of anesthesia and intraoperative blood pressure can decrease the incidence of postoperative neurocognitive dysfunction

Subjects will be recruited for the study and the protocol explained. In addition to standard American Society of Anesthesiologists (ASA) monitoring, we will monitor continuous non-invasive blood pressure and 4 lead electroencephalogram (EEG) channels. Patients will receive standardized anesthesia care in addition to a goal directed therapy hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).

Neurocognitive testing: In order to assess general cognitive function, the Montreal Cognitive Assessment test will be used. Cognitive function will be measured preoperatively and postoperatively at discharge, 1 month and 6 months after surgery. For delirium measurement, we will administer daily the Confusion Assessment Method (CAM-ICU) for up to 3 days.

The Montreal Cognitive Assessment (MoCA) is a screening tool to assess mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructionals skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.

The Wide Range Assessment of Memory and Learning (WRAML2) is a broad-based memory battery that provides a flexible measure of memory functioning and learning and takes approximately 45-60 minutes to administer. This assessment will be conducted at the first MRI visit and at the 6 month follow up.

The Confusion Assessment Method for the ICU (CAM-ICU) screens for the development of delirium and assesses four features: 1) acute change or fluctuation in mental status from baseline, 2) inattention, 3) altered level of consciousness, and 4) disorganized thinking. The CAM-ICU is positive, and the patient is considered to have delirium, if features 1 and 2 and either feature 3 or 4 are present.

Brain imaging: The timing of pre-operative brain imaging will be as allowed by patient factors and scanner availability, typically less than 15 days before surgery, when the patient comes for the preoperative evaluation, and postoperatively within 2 weeks after surgery.

Optional Blood Draws: Patients will be asked to provide 2 optional blood samples, drawn the day of their brain imaging visit and post-operatively (within 2 days). These samples will be used to asses blood inflammatory biomarkers in obstructive sleep apnea (OSA) subjects and non-OSA subjects between baseline and post-surgery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Taking Brain Monitoring to the Next Level
Actual Study Start Date :
Jan 30, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Patients monitored and receiving a standard anesthesia plan in addition of a goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).

Other: Goal directed therapy (GDT)
Goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).

Outcome Measures

Primary Outcome Measures

  1. Postoperative cognitive dysfunction [Preoperatively (within 15 days of surgery)]

    Montreal Cognitive Assessment (MoCA) test

  2. Postoperative cognitive dysfunction [postoperatively at discharge (within 2 weeks of surgery).]

    Montreal Cognitive Assessment (MoCA) test

  3. Postoperative cognitive dysfunction [6 months after surgery.]

    Montreal Cognitive Assessment (MoCA) test

  4. Postoperative Delirium [Daily for up to 3 days postoperatively]

    Confusion Assessment Method (CAM-ICU)

Secondary Outcome Measures

  1. Examining brain changes [Typically less than 15 days before surgery, when the patient comes for the preoperative evaluation, postoperatively at up to 48 hours after surgery, and 6 months post surgery]

    Using non-invasive magnetic resonance imaging based diffusion tensor imaging

  2. Examining brain changes II [postoperatively within 2 weeks of surgery]

    Using non-invasive magnetic resonance imaging based diffusion tensor imaging

  3. Examining brain changes III [6 months post surgery]

    Using non-invasive magnetic resonance imaging based diffusion tensor imaging

  4. Blood anti-inflammatory biomarkers [pre-operatively (within 15 days before surgery)]

    Assess blood inflammatory biomarkers (Il6, Il10, TNFa, IL1b, HMGB1) in OSA subjects and non-OSA subjects

  5. Blood anti-inflammatory biomarkers [post-operatively (within 2 days of surgery)]

    Assess blood inflammatory biomarkers (Il6, Il10, TNFa, IL1b, HMGB1) in OSA subjects and non-OSA subjects

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 45-75 years old,

  • undergoing abdominal, orthopedic, gynecological, or urological surgery

  • expected to stay in hospital for at least 24hours

Exclusion Criteria:
  • Substantial hearing impairment or inability to understand English, since there needs to be neurocognitive testing done

  • status post craniotomy

  • severe dementia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine Los Angeles California United States 90095

Sponsors and Collaborators

  • University of California, Los Angeles

Investigators

  • Principal Investigator: Susana Vacas, MD, PhD, University of California, Los Angeles

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Susana Vacas, MD, PhD, Assistant Professor-in-Residence, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT04246320
Other Study ID Numbers:
  • HDBRAIN 16-001040
First Posted:
Jan 29, 2020
Last Update Posted:
May 19, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Susana Vacas, MD, PhD, Assistant Professor-in-Residence, University of California, Los Angeles
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 19, 2022